Tanvex BioPharma, Inc. is a vertically integrated biopharmaceutical company specializing in the development, manufacturing, and commercialization of biosimilars and biologics. Founded in 2013 and headquartered in the Cayman Islands, Tanvex operates key facilities in San Diego, California, and Taipei, Taiwan. The company’s core products include biosimilars targeting therapeutic areas such as neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Tanvex also provides contract development and manufacturing organization (CDMO) services under the Bora Biologics brand, offering end-to-end biologics solutions including cell-line development, process development, GMP manufacturing, analytical development, and regulatory support. Its manufacturing capabilities encompass microbial fermentation and mammalian cell culture using state-of-the-art bioreactors and automated purification technologies, enabling the production of biologics with high quality and consistency.
In the last two years, Tanvex has undergone significant strategic changes, including the appointment of industry veteran Stephen Lam as CEO in September 2024 to lead global CDMO operations and biosimilar commercialization. The company completed the acquisition of Bora Biologics in January 2025, integrating Bora’s complementary large molecule CDMO services and manufacturing facilities, which expanded Tanvex’s biomanufacturing platform substantially with over 100,000 square feet of facility space and enhanced bioreactor capacity. Bora Pharmaceuticals became the largest shareholder following a strategic investment in mid-2025, supporting Tanvex’s global development and manufacturing capabilities, including new fill/finish services in Maryland, USA. Tanvex’s integrated operations across the US and Asia allow the company to efficiently address evolving market and regulatory demands while advancing its biosimilar and biologics pipeline.
Tanvex serves biopharmaceutical companies and healthcare markets globally, leveraging its comprehensive capabilities from R&D to commercial-scale production and regulated market approvals. The company emphasizes innovation and operational efficiency to deliver affordable, effective biologic therapies while maintaining stringent compliance with regulatory standards. Tanvex’s vertical integration strategy allows it to control the entire biopharma production process, ensuring quality, lowering costs, and accelerating time to market for its biosimilars and CDMO clients. The company continues to expand its portfolio and operational footprint with a focus on delivering impactful biopharmaceutical solutions worldwide.